Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.64 |
| ▸ | RAF1 | P04049 | 12/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546272 | 0.93 | BRAF (0.73) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL545886 | 0.93 | BRAF (0.73) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL545758 | 0.92 | BRAF (0.64) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL546043 | 0.92 | BRAF (0.63) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL546265 | 0.90 | BRAF (0.68) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL545770 | 0.89 | BRAF (0.60) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL5417941 | 0.88 | BRAF (0.61) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL546297 | 0.87 | BRAF (0.58) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL545793 | 0.87 | BRAF (0.58) | BRAFRAF1KCNH2EGFRLCK | |
| SCHEMBL545081 | 0.86 | BRAF (0.72) | BRAFRAF1KCNH2EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | BRAF 215/4885RAF1 198/4885KCNH2 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.